Cidara Therapeutics Q2 EPS $(0.14) Misses $(0.13) Estimate, Sales $7.61M Miss $11.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics reported Q2 losses of $(0.14) per share, missing the analyst consensus estimate of $(0.13) by 7.69%. The company also reported quarterly sales of $7.61 million, missing the analyst consensus estimate of $11.55 million by 34.08%. However, these figures represent an increase over the same period last year.
August 04, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cidara Therapeutics' Q2 results missed analyst estimates, which could negatively impact the stock in the short term.
Cidara Therapeutics reported lower than expected earnings and sales for Q2. This could lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100